Change-Makers for Asthma and Allergies 

After JR’s son was hospitalized several times due to his asthma, she came to AAFA for resources on how to help her son breathe. JR not only found the tools she was looking for, but she also found a passion to use her story to save lives through advocacy.

“Through my advocacy efforts for AAFA, I found purpose and a renewed sense of empowerment, not to mention the invaluable support of a community that understood the challenges firsthand – whether it’s connecting a parent with educational resources or raising money and awareness for more asthma and allergy research.” – JR, AAFA community member
 

Read more to see how AAFA is making a difference through research, education, advocacy, and support.

Putting Our Community's Needs First

Thanks to your support, AAFAleads and engages in research that contributes to scientific knowledge about asthma and allergies and saves lives.

AAFA ensures people with asthma and allergies are at the forefront of drug development. Researchers at universities, drug companies, and federal agencies (like the NIH and FDA) know they can come to AAFA and our highly engaged network to learn what matters most to people with asthma and allergies. And it’s all because of you!

Will you join in our mission to save and improve lives for people with asthma and allergies?

DONATE TODAY

RESEARCH NEWS

Here's the latest asthma and allergy research news:

Anaphylaxis

• New Research Highlights Factors Associated with Epinephrine Use in the Treatment of Anaphylaxis in Infants and Toddlers

• Aquestive Therapeutics Doses First Patient in Phase 3 Pivotal Clinical Study on Anaphylm™ (epinephrine) Sublingual Film

Asthma

• Study Finds Puerto Rican Black Latinx Populations in the United States Have Higher Risk of Emergency Department and Urgent Care Asthma Visits Than Other Black Subgroups
• Lower Socioeconomic Status May Help Explain Racial Disparities in Asthma and Atopic Dermatitis Prevalence

COPD

• DUPIXENT® Significantly Reduced COPD Exacerbations in Second Positive Phase 3 Trial

EoE

• EsoCap Reports Positive Topline Results from ACESO Phase II Trial Investigating ESO-101 in Eosinophilic Esophagitis

Food Allergy

• Alladapt’s Multiple Food Allergy Treatment Receives FDA Fast Track Designation

   

CLINICAL TRIALS

Are You Currently Taking Oral Corticosteroids (OCS) for Your Asthma?

Would you like to contribute to important new research? SUNRISE is a clinical study investigating whether a new biologic treatment called tezepelumab may help to reduce or remove the need for OCS in adults with severe asthma. The study is looking for people who:

• Are between 18 and 80 years of age
• Have had an asthma diagnosis for at least 1 year
• Have been taking OCS for asthma for at least 6 months
• Have been using inhaled corticosteroids for at least a year, and a long-acting beta 2-agonist (LABA) for at least 3 months
• Have not been receiving any biologic treatment for asthma for at least 4 months

Sponsored by AstraZeneca
 

LEARN MORE

Now Enrolling: The Vitesse Phase 3 Study for Peanut Allergy

The VITESSE phase 3 clinical research study is looking for children 4 to 7 years of age who have been diagnosed with peanut allergy and are currently following a strict peanut-free diet. Study doctors are testing an investigational drug patch (also called study drug patch) to learn how well it works and how safe it is in children with peanut allergy.

What should I know about the VITESSE study?
To be eligible for this study, participants must be*:

• 4 to 7 years of age

• Diagnosed with peanut allergy

• Currently following a strict peanut-free diet

*Other inclusion/exclusion criteria will apply.

• This study will consist of at least 12 study visits and 5 phone calls over a period of approximately 58 weeks (about 1 year)

• Participants will be randomly assigned (by chance) to receive the study drug patch or placebo patch (looks like the study drug but contains no active drug). Participants will have about a 67% (2 in 3) chance of receiving the study drug patch and about a 33% (1 in 3) chance of receiving the placebo patch

• The health and safety of participants will be monitored throughout the study

• Participant data and information will be kept confidential according to applicable laws for clinical research studies

• Study participants will receive all study-related procedures and the study drug patch or placebo patch at no cost

To learn more about the VITESSE phase 3 study and eligibility criteria, please visit VitesseAllergyStudy.com or ClinicalTrials.gov (identifier: NCT05741476).

Study sponsored by DBV Technologies

LEARN MORE

Now Accepting Patients for National Asthma Study

Are you a young adult between the ages of 18 and 30, African American or Black, with persistent asthma? Are you looking to get better control of your asthma? A national study is now accepting patients to test various mobile health programs. If you qualify for the study, you will be asked to use a mobile health program for about 10 weeks and complete four 30-minute questionnaires spread out over the course of one year. Everything is remote – you won’t have to come in for any study visits.

You will receive compensation for completing the study and will be given a Garmin physical activity tracker which you can keep after the study has ended.

Learn more about the study and see if you qualify.  

If you have any questions, please contact: 734-489-1949 or theathenaproject2022@gmail.com

LEARN MORE

INTERVIEWS AND FOCUS GROUPS

Now Recruiting: Nasal Polyps Focus Group 

AAFA, in partnership with PlatformQ Patient Education (PPE), is looking for people who manage nasal polyps to take part in a focus group. The focus group will give you a chance to share your firsthand experiences and needs while managing nasal polyps. Information learned from this focus group will help AAFA and PPE improve our education.

The time commitment will be about two hours. If selected for the focus group, you will receive a reward for your time. If you would like to participate in the focus group, please take this quick survey to see if you qualify.

Sponsored by PlatformQ

LEARN MORE 

Research Opportunity: Caregivers for Children with Asthma

A Doctor of Nursing Practice (DNP) student at Regis College is recruiting for a project about caregivers and how well they cope with mental health symptoms while caring for a child with asthma. Your participation may help other caregivers like you. To be eligible, you must:

• Have a child of any age with a diagnosis of asthma who requires albuterol or steroid inhalers for management
   
• Be 18 years of age or older 

You will be asked to complete a one-time, 15-minute survey about yourself and participate in a one-hour interview over Zoom in a group setting. You will be given a $10 Amazon e-gift card at the completion of this project.

If you have any questions, please contact Timarra Warren by email or phone at: twar860@regiscollege.edu or 470-541-8440
 

LEARN MORE

Share Your Thoughts on the Effects of Sesame Labeling

If you or someone you provide care for has a sesame allergy, we would like to ask you about recent sesame allergen labeling legislation. A project at the University of South Carolina is compiling stories to describe the impact of the FASTER Act on people managing sesame allergies. 

Contact Richie Holmberg at the University of South Carolina for more information and to participate in this study: holmberr@email.sc.edu
 

LEARN MORE

Ending Jan. 9, 2024! Health care providers: catch the continuing medical education (CME) program, “The Increasing Importance of Identifying Urticaria Subtypes to Achieve Control: Opportunities with T2 Inflammation Targeting Agents,” before it’s gone! Listen to an expert panel discuss urticaria diagnosis, treatment options, and relationships between triggers. Watch on demand now to earn AMA PRA Category 1 Credit™.

We are grateful for our 2023 corporate supporters. Their contributions allow us to offer education, advocacy, research, and support for people managing asthma and allergies. 

Did You Miss Our Last Issue?

Check out our most recent issue for news on food allergy labeling, epinephrine access, and more.
 

                                   READ THE LATEST ISSUE

Thank you for your continued support.
Visit aafa.org, aafa.org/certified, kidswithfoodallergies.org